Physician profile

Mark Robert Link

General Practice (Dentist) · Greenwood Village, CO

NPI 1043422231

$727.47

in general payments reported to CMS, 2019-2025

7 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$40.60

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Geistlich Pharma, North America, INC. $342.84 2019
Align Technology, INC. $185.20 2020-2021
Dentsply Sirona INC $120.76 2020-2021
Biohorizons Implant Systems INC. $38.07 2021-2022
American Orthodontics Corporation $20.13 2023 Lp and Ifit Tubes, Master Series, Radiance
Philips North America LLC $15.47 2024 (E17) Power Toothbrush Und
Kettenbach Lp $5.00 2024

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Mark Robert Link

$727.47

in general payments reported 2019-2025

Years
2019-2024
Top company
Geistlich Pharma, North America, INC.

https://glasscript.com/doctor/364594/mark-robert-link

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.